Palbociclib
- PDF / 171,797 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 78 Downloads / 147 Views
1 S
Palbociclib Dermatitis, dysphagia, pain, neutropenia and febrile neutropenia: 5 case reports.
In a retrospective study involving 30 women who had received concurrent palbociclib and irradiation for metastatic breast cancer at an institute in France between April 2017 and August 2019, 5 women [ages not stated] were described, who developed dermatitis, pain and febrile neutropenia (1 patient), dysphagia, dermatitis and neutropenia (1 patient), dysphagia (1 patient), pain (1 patient) or colitis (1 patient) during treatment with palbociclib for metastatic breast cancer. All the five women, who had ER positive metastatic breast cancer, started receiving irradiation at metastatic site along with palbociclib 125mg daily [routes not stated] from day 1 to day 21, of every 28 days cycle. All the women subsequently developed toxicities, which manifested as grade 3 dermatitis, pain and febrile neutropenia (n=1), grade ≥2 dysphagia, dermatitis and neutropenia (n=1), grade 2 dysphagia (n=1) and grade 3 pain (n=1) and grade 1 colitis (n=1) [durations of treatments to reactions onset not stated]. The therapy with palbociclib was discontinued in two of these five women [outcomes not stated]. Beddok A, et al. Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature. British Journal of Cancer 123: 905-908, No. 6, 15 803506800 Sep 2020. Available from: URL: http://doi.org/10.1038/s41416-020-0957-9
»
Editorial comment: Details of two of these patients [who developed dermatitis, pain and febrile neutropenia (1 patient), and dysphagia, dermatitis and neutropenia (1 patient)] have previously been published and processed for Adis PV [see Reactions 1823 p280; 803503065].
0114-9954/20/1826-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 17 Oct 2020 No. 1826
Data Loading...
